Understand the businesses building the longevity economy.
Explore 150 companies, clinics, and vendors. Compare what they offer, who they serve, their pricing, and their business models.
What’s new—and why it matters. The free weekly briefing on science, companies and capital shaping longevity.
Read back issuesExplore 150 companies, clinics, and vendors. Compare offerings, customers, pricing, and business models.
Free subscribers can explore Atlas 150 at no charge through October 31, 2026. No credit card required for this access. Atlas 50 remains available without registration.
Explore Atlas 150Original reporting by Rick Polito on the people and business models behind the headlines.
Deep Dives are free to LongevityBiz subscribers through October 31, 2026. Premium access for Deep Dive 4 onward is planned from November 1; Deep Dives 1–3 remain free. The newsletter is always free.
Browse Deep DivesPremium includes ongoing access to the expanded Atlas 150, with 100 additional in-depth profiles of companies, vendors, and clinics. Free subscribers can explore Atlas 150 at no charge through October 31, 2026. Existing Premium billing is unchanged.
$15 per month or $125 per year.
View Premium plansAlready Premium? Sign in to Atlas with your LongevityBiz subscription email, or log in to read Deep Dives. You do not need to buy a second subscription.
We help readers understand which longevity signals are becoming real business—and which are not.
LongevityBiz was launched by Dr. Skye Lininger and Rick Polito to follow how advances in medicine become credible products, care models, reimbursement pathways, and markets.
Dr. Lininger founded Healthnotes and built media and software properties across the wellness market, including tools for tracking products and ingredients in the supplement industry. He has written or contributed to a dozen books.
Rick Polito is Editor-in-Chief of LongevityBiz. An award-winning journalist and former editor-in-chief of Nutrition Business Journal, he has spent decades chronicling the opportunities, challenges, and credibility problems shaping health markets.
Together, they bring operating, market, and editorial discipline to the emerging longevity economy—and a shared commitment to separating signal from hype.